Methods and systems for providing gender specific pharmaceuticals

Patent metadata

Field	Value
Publication number	US-9750612-B2
Application number	US-201615071965-A
Country	US
Kind code	B2
Filing date	Mar 16, 2016
Priority date	Jun 15, 2005
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The present disclosure provides a system of gender specific pharmaceuticals. The system includes a first package of a pharmaceutical for use by a male and a second package of a pharmaceutical for use by a female. The first package includes at least one male dosage having a first dosage amount, an insert positioned in the first package, the insert including a recommended male dosage and a recommended female dosage that is different than the male dosage, and a male label coupled to the first package, the label including a male gender specifier. The female package includes at least one female dosage having a second dosage amount that is smaller than the first dosage amount, an insert positioned in the first package, the insert including a recommended male dosage and a recommended female dosage that is different than the male dosage, and a female label coupled to the second package, the female label including a female gender specifier, wherein the female gender specifier is different than the male gender specifier.

First claim

What is claimed is:

1. A method for providing gender specific pharmaceuticals, the method comprising:
providing a first package comprising a pharmaceutical for use by a male, wherein the pharmaceutical comprises a central nervous system depressant, the first package comprising:
at least one male dosage having a first dosage amount;
a first insert positioned in the first package, the first insert including a recommended male dosage and a recommended female dosage that is different than the male dosage; and
a first label coupled to the first package, wherein at least one of the provided first label and first package includes a male gender specifier; and
providing a second package comprising a pharmaceutical for use by a female, wherein the pharmaceutical comprises a central nervous system depressant, the second package comprising:
at least one female dosage having a second dosage amount, wherein the first dosage amount is larger than the second dosage amount;
a second insert positioned in the second package, the second insert including a recommended male dosage and a recommended female dosage that is different than the male dosage; and
a second label coupled to the second package, wherein at least one of the provided second label and second package includes a female gender specifier, wherein the female gender specifier is different than the male gender specifier.

2. The method of claim 1 , wherein at least a portion of the female dosage includes a gender specifier.

3. The method of claim 2 , wherein the gender specifier is a pink color that covers at least a portion of the female dosage.

4. The method of claim 1 , wherein the at least one male dosage and the at least one female dosage is at least one of an oral medication and an intravenous medication.

5. The method of claim 4 , wherein the at least one male dosage and the at least one female dosage is at least one of a tablet, capsule, powder, and liquid.

6. The method of claim 1 , wherein at least a portion of the first package includes a gender specifier.

7. The method of claim 6 , wherein the gender specifier is a color that is at least one of blue and green.

8. The method of claim 1 , wherein least a portion of the second package includes a gender specifier.

9. The method of claim 8 , wherein the gender specifier is a color that is at least one of pink and purple.

10. The method of claim 1 , wherein at least a portion of the first package includes a male gender specifier that is at least one of blue and green color and wherein at least a portion of the second package includes a female gender specifier that is at least one of pink and purple color.

11. The method of claim 1 , wherein at least one of the first insert and the second insert further comprises a recommended male dosage and a recommended female dosage that is different than the male dosage regardless of weight or body mass index.

12. The method of claim 1 , wherein at least one of the first and second packages includes an RFID label.

13. A system of gender specific pharmaceuticals, the system comprising:
a first package comprising a pharmaceutical for use by a male, wherein the pharmaceutical comprises a central nervous system depressant, the first package comprising:
at least one male dosage having a first dosage amount;
a first insert positioned in the first package, the first insert including a recommended male dosage and a recommended female dosage that is different than the male dosage; and
a first label coupled to the first package, wherein at least one of the provided first label and first package includes a male gender specifier; and
a second package comprising a pharmaceutical for use by a female, wherein the pharmaceutical comprises a central nervous system depressant, the second package comprising:
at least one female dosage having a second dosage amount that is smaller than the first dosage amount;
a second insert positioned in the second package, the second insert including a recommended male dosage and a recommended female dosage that is different than the male dosage; and
a second label coupled to the second package, wherein at least one of the provided second label and second package includes a female gender specifier, wherein the female gender specifier is different than the male gender specifier.

14. The system of claim 13 , wherein at least a portion of the female dosage includes a gender specifier.

15. The system of claim 14 , wherein the gender specifier is a pink color that covers at least a portion of the female dosage.

16. The system of claim 13 , wherein the at least one male dosage and the at least one female dosage is at least one of an oral medication and an intravenous medication.

17. The system of claim 16 , wherein the at least one male dosage and the at least one female dosage is at least one of a tablet, capsule, powder, and liquid.

18. The system of claim 13 , wherein at least a portion of the first package includes a gender specifier.

19. The system of claim 18 , wherein the gender specifier is a color that is at least one of blue and green.

20. The system of claim 13 , wherein least a portion of the second package includes a gender specifier.

21. The system of claim 20 , wherein the gender specifier is a color that is at least one of pink and purple.

22. The system of claim 13 , wherein at least a portion of the first package includes a male gender specifier that is at least one of blue and green color and wherein at least a portion of the second package includes a female gender specifier that is at least one of pink and purple color.

23. The system of claim 13 , wherein at least one of the first and second packages includes an RFID label.

24. The system of claim 13 , wherein at least one of the first insert and the second insert further comprises a recommended male dosage and a recommended female dosage that is different than the male dosage regardless of weight or body mass index.

25. A method for providing gender specific pharmaceuticals, the method comprising:
providing a first package comprising a pharmaceutical for use by a male, wherein the pharmaceutical comprises a central nervous system depressant, the first package comprising:
at least one male dosage having a first dosage amount; and
a first label coupled to the first package, the label including a male gender specifier; and
providing a second package comprising a pharmaceutical for use by a female, wherein the pharmaceutical comprises a central nervous system depressant, the second package comprising:

at least one female dosage having a second dosage amount that is different than the first dosage amount; and
a second label coupled to the second package, the second label including a female gender specifier, wherein the female gender specifier is different than the male gender specifier.

26. The method of claim 25 , wherein at least a portion of the first package includes a male gender specifier that is at least one of blue and green color and wherein at least a portion of the second package includes a female gender specifier that is at least one of pink and purple color.

27. The method of claim 25 , wherein at least a portion of the female dosage includes a gender specifier that is a pink color covering at least a portion of the female dosage.

28. A system of gender specific pharmaceuticals, the system comprising:
a first p

Assignees

• P Tech Llc

Inventors

• Bonutti Peter M

Classifications

• A61F2002/305

  Snap connection · CPC title

• A61F2002/30092

  using shape memory or superelastic materials, e.g. nitinol · CPC title

• A61F2002/30364

  Rotation about the common longitudinal axis · CPC title

• A61F2002/3863

  Condyles fitted on an anchored base · CPC title

• A61F2/3877

  Patellae or trochleae · CPC title